Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Frequently asked questions
What sector does Iambic Therapeutics, Inc. Common Stock (IAM) operate in?
Iambic Therapeutics, Inc. Common Stock belongs to the Other sector and operates in the Biotechnology industry.
What is Iambic Therapeutics, Inc. Common Stock (IAM) current stock price?
As of the latest data, Iambic Therapeutics, Inc. Common Stock stock price is $14.00, with a previous close of $14.41. Iambic Therapeutics, Inc. Common Stock lost -$0.41 in the last trading session, representing a -2.85% loss.
What is Iambic Therapeutics, Inc. Common Stock (IAM) current market capitalization?
Iambic Therapeutics, Inc. Common Stock market cap is approximately 663.61 million.
What is Iambic Therapeutics, Inc. Common Stock (IAM) Earnings Per Share (EPS)?
The trailing EPS is -$2.69.
Does Iambic Therapeutics, Inc. Common Stock (IAM) pay dividends?
No. Iambic Therapeutics, Inc. Common Stock does not pay a dividend.
What is Iambic Therapeutics, Inc. Common Stock (IAM) beta (volatility) score?
Iambic Therapeutics, Inc. Common Stock has a beta of 0.000, indicating lower volatility than the overall market.
